- Home
- GLRE vs CELC Comparison
GLRE vs CELC Comparison
Compare GLRE & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLRE
- CELC
- Stock Information
- Founded
- GLRE 2004
- CELC 2011
- Country
- GLRE Cayman Islands
- CELC United States
- Employees
- GLRE N/A
- CELC N/A
- Industry
- GLRE Property-Casualty Insurers
- CELC Medical Specialities
- Sector
- GLRE Finance
- CELC Health Care
- Exchange
- GLRE Nasdaq
- CELC Nasdaq
- Market Cap
- GLRE 486.3M
- CELC 489.7M
- IPO Year
- GLRE 2007
- CELC 2017
- Fundamental
- Price
- GLRE $14.12
- CELC $10.93
- Analyst Decision
- GLRE
- CELC Strong Buy
- Analyst Count
- GLRE 0
- CELC 6
- Target Price
- GLRE N/A
- CELC $29.17
- AVG Volume (30 Days)
- GLRE 83.9K
- CELC 356.6K
- Earning Date
- GLRE 03-04-2025
- CELC 11-14-2024
- Dividend Yield
- GLRE N/A
- CELC N/A
- EPS Growth
- GLRE N/A
- CELC N/A
- EPS
- GLRE 2.53
- CELC N/A
- Revenue
- GLRE $702,254,000.00
- CELC N/A
- Revenue This Year
- GLRE N/A
- CELC N/A
- Revenue Next Year
- GLRE N/A
- CELC N/A
- P/E Ratio
- GLRE $5.58
- CELC N/A
- Revenue Growth
- GLRE 8.96
- CELC N/A
- 52 Week Low
- GLRE $11.01
- CELC $10.35
- 52 Week High
- GLRE $15.82
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- GLRE 51.61
- CELC 35.65
- Support Level
- GLRE $13.42
- CELC $10.35
- Resistance Level
- GLRE $14.31
- CELC $13.80
- Average True Range (ATR)
- GLRE 0.29
- CELC 0.83
- MACD
- GLRE 0.06
- CELC -0.19
- Stochastic Oscillator
- GLRE 78.65
- CELC 16.20
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed, and income from investments.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.